ATAP Sends Administration Letter Supporting Proposed "Rebate Rule"
ATAP thanks the Administration for beginning to correct the perverse incentives in our drug supply chain that have caused sharply increasing list prices and ever-climbing out-of-pocket burdens for patients. We support elimination of the antikickback safe harbor for rebate payments from pharmaceutical manufacturers to PBMs. We also encourage the Administration’s vigilance to ensure that arrangements mimicking rebates do not crop up in their place. ATAP supports allowing manufacturers to provide discounts directly to patients at the point-of-sale and notes that this reform will remove barriers to manufacturers lowering drug prices.